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a b s t r a c t
The RNA genome of human immunodeﬁciency virus type 1 (HIV-1) is enclosed by a capsid shell that
dissociates within the cell in a multistep process known as uncoating, which inﬂuences completion of
reverse transcription of the viral genome. Double-stranded viral DNA is imported into the nucleus for
integration into the host genome, a hallmark of retroviral infection. Reverse transcription, nuclear entry,
and integration are coordinated by a capsid uncoating process that is regulated by cellular proteins.
Although uncoating is not well understood, recent studies have revealed insights into the process,
particularly with respect to nuclear import pathways and protection of the viral genome from DNA
sensors. Understanding uncoating will be valuable toward developing novel antiretroviral therapies for
HIV-infected individuals.
& 2014 Elsevier Inc. All rights reserved.
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Introduction
As a retrovirus, HIV-1 infection requires reverse transcription of
its single-stranded RNA genome into double-stranded DNA that is
translocated into the nucleus and integrated into host cell chro-
matin. Cellular transcription results in synthesis of viral genomic
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RNA and proteins that assemble at the host cell plasma membrane
for release as virions. Before these events can proceed, disassem-
bly of a protective, conical capsid around the HIV-1 genome occurs
after virus entry into the cell, in a process known as uncoating.
Uncoating of the HIV-1 core is highly regulated and plays a
critical role during early post-entry stages of infection. The core
consists of a conical viral capsid composed of a polymer of capsid
protein (CA) subunits encasing the viral RNA genome and asso-
ciated proteins, including nucleocapsid (NC), reverse transcriptase
(RT), and integrase (IN). While still not completely understood,
uncoating is likely a multistep process that begins with loosening
or a small opening of the capsid, followed by stripping of most or
all CA monomers from the core prior to entry into the nucleus.
Perturbation of uncoating has detrimental effects on downstream
replication steps and, ultimately, infectivity. For example, CA
mutations that alter the intrinsic stability of the viral capsid lead
to signiﬁcant reduction in reverse transcription, trafﬁcking of
viral DNA to the nucleus, and infectivity. Because of the highly
ordered nature of capsid dissociation required for viral infectivity
and the unique structure of HIV-1 mature capsid that is intole-
rant of mutations, uncoating is a favorable target for antiretroviral
therapy.
Complicating matters, however, the mechanism of uncoating
likely requires several host cell proteins and trafﬁcking pathways
and is difﬁcult to study in vivo. Uncoating appears to be inﬂuenced
by cell type-speciﬁc factors and may vary in different cells. Our
understanding of HIV-1 uncoating results mostly from studies
of viral mutants and host factors, together with biochemical
characterization of HIV-1 cores in vitro.
Structure of the HIV-1 core
The HIV-1 genome, like that of all retroviruses, encodes the Gag
polyprotein that has three major domains: matrix (MA), CA, and
NC. Gag oligomerizes in an infected cell at the plasma membrane
for assembly and release into immature virions that have a
spherical shaped core associated with the viral membrane (Fuller
et al., 1997). Cleavage of Gag by HIV-1 protease leads to release of
the each of the three mature proteins and further assembly into
the mature core, which, unlike many retroviruses, is conical in
shape. Although immature HIV-1 particles contain approximately
5000 Gag molecules, only 1000–1,500 CA molecules assemble into
the mature capsid that encases the two packaged copies of the
viral RNA genome (Briggs et al., 2004).
HIV-1 CA is a two-domain protein consisting primarily of alpha
helices. Recombinant CA and CA-NC proteins can assemble in vitro
into tubes and spheres, some of which resemble mature, conical
cores (Campbell and Vogt, 1995; Ehrlich et al., 1992). The HIV-1
capsid was originally modeled as a lattice of CA hexamers that is
closed by the insertion of 12 pentamers (Ganser et al., 1999). Two
structures obtained from cryo-electron microscopy, and conﬁrmed
by crystallography, of in vitro assembled HIV-1 CA showed hex-
amers that are stabilized by an inner ring of six amino-terminal
domains (NTDs) and an outer “girdle” of carboxyl-terminal
domains (CTDs) that also form intersubunit contacts with adjacent
NTDs. (Ganser-Pornillos et al., 2007; Li et al., 2000; Pornillos et al.,
2009). The CTD also forms dimeric and trimeric interfaces con-
necting the hexamers. The native viral capsid is continuously
curved, likely as a result of the ﬂexibility of CTD dimers, particu-
larly in helices 9 and 10 (Byeon et al., 2009; Zhao et al., 2013).
As mentioned above, the CA CTD also forms a trimer interface
between hexamers, in which helix 10 of one hexamer interacts
with helix 11 from an adjacent hexamer; this interface also plays
a role in disassembly of the core (uncoating) in target cells
(Byeon et al., 2009). Several amino acid substitutions in these
helices destabilize or hyperstabilize cores, leading to loss of viral
infectivity (Byeon et al., 2009; Forshey et al., 2002; von Schwedler
et al., 2003; Zhao et al., 2013). Moreover, inter-hexamer cross-
linking of introduced cysteine residues within the trimer interface
resulted in resistance to in vitro disruption mediated by rhesus
macaque TRIM5α (rhTRIM5α), which is discussed in more detail
below (Zhao et al., 2011).
Experimental approaches to study uncoating
HIV-1 uncoating has been challenging to study owing to a lack
of speciﬁc and sensitive assays to measure or visualize this
process. In addition, cores from viruses and in vitro assembled
structures are heterogeneous and many are defective, making it
difﬁcult to examine individual cores. Over the years, several in vivo
and in vitro approaches have been used to study this process
indirectly and are described here.
RTC/PIC isolation and biochemical characterization
Several groups have employed biochemical assays to isolate
and characterize reverse transcription complexes (RTCs) or pre-
integration complexes (PICs) recovered from the cytoplasm of
freshly-infected cells (Bukrinsky et al., 1993; Farnet and
Haseltine, 1991; Fassati and Goff, 2001; Gendelman et al., 1990;
Karageorgos et al., 1993; Miller et al., 1997). Cytoplasmic extracts
from HIV-infected cells, obtained by gentle detergent treatment or
hypotonic lysis, are fractionated over sucrose gradients by ultra-
centrifugation. Fractions containing viral DNA sequences, which
are present during and upon completion of reverse transcription,
can be evaluated by multiple biochemical assays for the presence
of viral and host proteins, viral nucleic acids, and functional assays.
In vitro reverse transcription and integration assays can be
performed with RTCs/PICs isolated under different conditions or
in the presence or absence of cellular factors.
Proteins detected in association with viral DNA include MA, IN,
RT, and Vpr, whereas little or no detectable CA remains. Differ-
ences in protein content observed by different researchers could
be due to the timing of sample collection after infection and
variations in the methods used to extract cytoplasmic fractions
and to perform sedimentation. The early observation that these
complexes generally lack CA suggested that uncoating occurs
rapidly in target cells. However, HIV-1 capsid might be fragile
and lost from the RTC/PIC during the isolation procedures. More-
over, as discussed below, subsequent studies also demonstrated a
critical requirement for capsid stability in reverse transcription,
arguing that uncoating is completed later in the life cycle. None-
theless, the timing of uncoating, and whether it is progressive or
cooperative, are questions yet to be deﬁnitively answered.
In vitro capsid stability and disassembly assay
HIV-1 cores can be isolated from viruses and assayed for
disassembly in vitro (Forshey et al., 2002; Shah and Aiken, 2011).
The process involves overlaying HIV-1 virions onto a layer of
detergent atop a sucrose gradient. During ultracentrifugation at
4 1C, the viral membrane is removed through the detergent and
multiple fractions are obtained throughout the gradient. Fractions
that contain pelletable CA are characterized as lacking the envel-
ope proteins gp41 and gp120 but containing viral RNA, RT, and IN
(Forshey and Aiken, 2003; Forshey et al., 2002). Dissociation of CA
from the puriﬁed cores can be measured after incubation at 37 1C
and ultracentrifugation. Intact cores will be pelletable, whereas
disassembled cores result in dissolution of CA. Similar to isolated
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RTCs/PICs, reverse transcription can be assayed with cores isolated
from virions under various conditions (Warrilow et al., 2008).
Viral genetics: mutations and chimeric viruses
Several research groups noticed that mutations in the CA
region of Gag inﬂuence early events in the HIV-1 life cycle,
including initiation or completion of reverse transcription (Reicin
et al., 1996; Tang et al., 2001). Likewise, in vitro core stability can be
altered by introduction of CA mutations, leading to unstable or
hyperstable capsids and loss of virus infectivity (Forshey et al.,
2002). Characterization of speciﬁc mutants can reveal important
sites for binding host cell factors or alterations in the capsid
structure, both of which may provide insight into uncoating
mechanisms (Abdurahman et al., 2007; Brun et al., 2008;
Dismuke and Aiken, 2006; Fitzon et al., 2000; Li et al., 2009;
Misumi et al., 2010; Noviello et al., 2011; Qi et al., 2008; Scholz
et al., 2005; Tang et al., 2001, 2003, 2007; von Schwedler et al.,
2003; Wacharapornin et al., 2007; Yang et al., 2012; Yufenyuy and
Aiken, 2013).
Another experimental approach involves replacement of HIV-1
CA with CA from other retroviruses, such as murine leukemia virus
(MLV) or simian immunodeﬁciency virus (SIV). Studies of such
chimeric viruses have revealed virus–host interactions involved in
infection of speciﬁc cell types, including simian cells and non-
dividing cells (Cowan et al., 2002; Fujita et al., 2001; Hatziioannou
et al., 2006; Yamashita and Emerman, 2004). Comparison to wild-
type HIV-1 and other retroviruses provides insight into species-
speciﬁc factors that inﬂuence HIV-1 post-entry steps as well as
structural differences that affect uncoating.
Cellular genetics: protein knockdowns and expression
of restriction factors
Small interfering RNA (siRNA) has been employed in numerous
studies to determine whether speciﬁc host cell proteins control
the early steps of HIV-1 infection. Most notably, in 2008 three
groups screened siRNA libraries to identify multiple proteins
involved in early HIV-1 life cycle events (Brass et al., 2008; Konig
et al., 2008; Zhou et al., 2008). Further characterization of several
of the knockdowns, discussed later, showed that the correspond-
ing host proteins bind to HIV-1 CA and are required for proper
reverse transcription and nuclear entry.
Conversely, factors thought to inﬂuence uncoating can be
expressed in cells to study the kinetics or inhibition of HIV-1
uncoating. The HIV-1 capsid is targeted by primate-speciﬁc
restriction factors. Two nonhuman primate proteins, rhTRIM5α
and an owl monkey fusion of TRIM5α and cyclophilin A (CypA),
TRIMCyp, bind to the capsid and inhibit infection when expressed
in cells (Ganser-Pornillos et al., 2011; Sayah et al., 2004; Stremlau
et al., 2004; Yap et al., 2004). These factors are partly responsible
for the inability of HIV-1 to replicate inefﬁciently in the cells of
many nonhuman primates. Like unstable mutant CA cores, these
restriction factors lead to premature uncoating of HIV-1 when
expressed in target cells, and can disrupt capsid-like CA assemblies
in vitro (Black and Aiken, 2010; Chatterji et al., 2006; Diaz-Griffero
et al., 2007; Langelier et al., 2008; Stremlau et al., 2006; Zhao et al.,
2011). Induction of premature uncoating by rhTRIM5α is also
associated with inhibition of reverse transcription (Stremlau
et al., 2004; Yap et al., 2006) and requires proteasome activity in
target cells (Anderson et al., 2006; Kutluay et al., 2013; Wu et al.,
2006). These effects are abolished by speciﬁc mutations in the
TRIM5α RING domain, implicating ubiquitin ligase activity in the
mechanism (Roa et al., 2012).
Pharmacological approaches
Several small molecule HIV-1 inhibitors target CA, with many
of these disrupting immature particle assembly or maturation, late
steps in the viral life cycle (Lemke et al., 2012; Li et al., 2003; Tang
et al., 2003; Ternois et al., 2005; Zhang et al., 2008). However,
some CA-binding compounds have been identiﬁed that act during
post-entry steps of infection, which would suggest that they
perturb uncoating. The ﬁrst compound in this class, PF-3450074
(PF74), was shown to destabilize HIV-1 capsid after entry into cells
(Blair et al., 2010; Shi et al., 2011). Crystallization of PF74 with the
N-terminal domain of CA suggested that the compound binds in a
pocket formed by helices 3, 4, 5, and 7 (Blair et al., 2010), which is
distinct from the binding site of the late stage inhibitors men-
tioned above. PF74 stimulated the uncoating of puriﬁed HIV-1
cores in vitro, and decreased the recovery of pelletable CA upon
lysis of target cells, suggesting that the compound induces
premature uncoating. An HIV-1 mutant selected for PF74 resis-
tance acquired mutations in helices 4 and 5 (Q67H, K70R, T107N,
L111I) and in the CypA binding loop (H87P). These changes
collectively conferred strong resistance to the inhibitor by redu-
cing binding (Blair et al., 2010; Shi et al., 2011). They also stabilized
the viral capsid in vitro and delayed its opening in the target cell
(Xu et al., 2013). Interestingly, two other molecules, BI-1 and BI-2,
were reported to bind at the same CA site as PF74 but stabilized
in vitro CA-NC tubes and inhibited HIV-1 infection (Lamorte et al.,
2013). Structural analysis showed that the BI compounds interact
with the same site as PF74, but occupy a smaller volume within
the pocket. Another small molecule, and its derivative I-XW-053,
were designed to bind at a novel site at the NTD–NTD interface,
interacting with residues I37 in helix 2 and R173 in helix 8
(Kortagere et al., 2012). Like PF74, this compound also reduced
early reverse transcripts, suggesting that uncoating was altered.
Collectively, these studies demonstrate that the HIV-1 capsid is a
viable target for antiviral development.
Imaging assays
Visualization of HIV-1 uncoating in vivo using ﬂuorescence or
electron microscopy techniques is challenging, mainly due to the
dynamic process itself and inefﬁcient labeling of viral proteins or
genomes during infection. While some viral PIC components, such
as Vpr and IN, can be tagged without apparent loss of function
(Albanese et al., 2008; Arhel et al., 2006; McDonald et al., 2002),
introduction of ﬂuorophores on CA without disruption of proteo-
lytic processing and proper assembly into cores has proven to be
technically challenging. Phenotypic mixing of WT CA and CA
containing a small tetracysteine (TC) that can be labeled by a
ﬂuorescent dye can generate particles suitable for imaging studies
(Campbell et al., 2008). TC-tagged CA was shown to co-localize
with GFP-tagged rhTRIM5α and mCherry-Vpr. To monitor reverse
transcription, ﬂuorescently tagged deoxynucleotides (dNTPs) were
microinjected into cells and were co-localized with tagged-Vpr
after infection (McDonald et al., 2002), but the background
and technical challenges of this procedure make it impractical.
Antibody staining of ﬁxed, HIV-infected cells showed that CA is
co-localized with ﬂuorescently labeled Vpr, IN, dNTPs, or viral RNA,
but co-localization was rare and the procedure cannot be used for
continuous monitoring during infection (Albanese et al., 2008;
Arhel et al., 2006, 2007; Campbell et al., 2008; Hulme et al., 2011;
McDonald et al., 2002; Xu et al., 2013). However, a recent study
employed ﬂuorescently tagged APOBEC3F that was incorporated
into virions and remained associated with RTCs and PICs following
entry into the nucleus (Burdick et al., 2013), which may permit
tracking of these complexes in real time. Additionally, our group
has shown that modiﬁed uridines, which can react with a speciﬁc
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ﬂuorescent dye, can be introduced into the viral RNA genome (Xu
et al., 2013). The dye appeared to access the viral RNA only after
opening of the capsid in vivo or in the presence of cellular factors
in vitro, thus providing a novel probe for genome accessibility
during the early steps of HIV-1 infection.
Electron microscopy has revealed intriguing higher resolution
viral structures in vivo. Correlative 3-dimensional live-cell and
electron microscopy revealed RTCs by ﬂuorescent Vpr and dNTPs
(McDonald et al., 2002). Also using correlative cryo-EM using Vpr-
labeled virions, intact HIV-1 capsids could be visualized in the
cytoplasm of infected cells (Jun et al., 2011). Gold labeling of anti-
CA antibodies also revealed CA particles in infected T cell lines
near the nuclear pore (Arhel et al., 2007). However, more efﬁcient
methods are necessary to detect these infrequent complexes
within the vast cytoplasm to make this approach practical for
addressing biological questions.
Capsid stability affects reverse transcription and infectivity
The viral capsid inﬂuences HIV-1 reverse transcription. Bio-
chemical assays of RTCs or PICs from cells do not contain
detectable CA, suggesting that the capsid disassembles prior to
or during reverse transcription. While these assays may not be
able to detect partially intact cores or may strip loosened capsids
from the complexes, several CA mutations that altered in vitro core
stability resulted in reduced reverse transcripts and loss of
infectivity in cells, indicating that uncoating and reverse transcrip-
tion are coupled (Forshey et al., 2002; Rihn et al., 2013; von
Schwedler et al., 2003). A CA mutant, N74D, exhibited diminished
infectivity in speciﬁc cell lines and was hypersusceptible to
inhibition by non-nucleoside reverse transcriptase inhibitors
(NNRTIs), indicating that core opening may be accelerated for
the mutant (Ambrose et al., 2012). Moreover, results from two
in vivo imaging assays of wild-type HIV-1 using anti-CA antibodies
suggested that the majority of the capsid is undetectable within
60 min after virus entry, suggesting that initiation of uncoating
precedes the completion of reverse transcription (Hulme et al.,
2011; Xu et al., 2013). Collectively, these studies indicate that the
proper timing of HIV-1 uncoating is important for productive viral
DNA synthesis.
Completion of HIV-1 reverse transcription may require at least
partial capsid dissociation. Viral DNA synthesis requires cellular
factors (Warren et al., 2012; Warrilow et al., 2009), many of which
likely cannot access RTCs prior to capsid opening in the target cell.
On the other hand, it has been also hypothesized that reverse
transcription itself may promote uncoating, as the size and rigidity
of the nascent HIV-1 RNA-DNA hybrid or double-stranded DNA
genome may not physically ﬁt inside the core, thus destabilizing it
(Hulme et al., 2011). To study the kinetics of HIV-1 uncoating in
cells, Hulme and colleagues infected cells expressing TRIMCyp in
the presence of cyclosporine A (CsA), which binds to the CypA
portion of the restriction factor and prevents it from binding to CA.
CsA was subsequently washed out of the cells at different time
points in the presence and absence of the NNRTI. The results
indicated that delaying reverse transcription prolonged the period
of susceptibility to inhibition by TRIMCyp, suggesting that reverse
transcription accelerates capsid dissociation. However in other
studies, RT inhibitors or mutations in RT that prevent reverse
transcription did not alter the kinetics of capsid dissociation
in vitro and in vivo (Kutluay et al., 2013; Xu et al., 2013). Another
study suggested that inhibition of reverse transcription reduces
the extent of uncoating in target cells and renders HIV-1 resistant
to rhTRIM5α (Yang et al., 2013). Although some of these studies
appear contradictory, the assays may reﬂect different detection
abilities or different stages of the uncoating process. Indeed, our
imaging-based uncoating assays of the CA mutant, E45A, which
contains a hyperstable capsid (Forshey et al., 2002; Jun et al.,
2011), showed early opening of the core without complete capsid
disassembly and accelerated production of reverse transcripts
compared to wild-type virus (Xu et al., 2013). Thus, uncoating
may occur in multiple steps, with early opening of the HIV-1
capsid preceding its complete dissociation from the viral ribonu-
cleoprotein complex in target cells.
Cellular CypA inﬂuences HIV-1 uncoating and nuclear entry
The HIV-1 capsid likely interacts with multiple host cell factors
for proper uncoating kinetics and trafﬁcking of the viral genome to
the nucleus. The best-characterized human protein that binds to
CA cores and facilitates HIV-1 replication is CypA, a peptidylprolyl
isomerase that is packaged into HIV-1 virions through interactions
with the CA domain of Gag (Luban et al., 1993). CA binds to CypA
via an extended NTD loop between helices 4 and 5, with amino
acids Gly89 and Pro90 (Gamble et al., 1996) bound at the active
site of the enzyme. CypA catalyzes the cis/trans isomerization of
the peptide bond between G89 and P90 (Bosco et al., 2002).
Although virions incorporate CypA, it is mainly required for HIV-1
infection in the target cell and its packaging into virions does not
appear to play a role in replication (Hatziioannou et al., 2005;
Sokolskaja et al., 2004). Inhibiting CypA binding to CA by treat-
ment of infected cells with CsA or a similar drug reduces HIV-1
DNA levels, suggesting that CypA may inﬂuence uncoating
(Braaten et al., 1996b; Ptak et al., 2008). CypA also sensitizes
HIV-1 to restriction by rhTRIM5α and PF74, further suggestive of
modulation of uncoating.
In vivo selection or mutagenesis studies identiﬁed several
amino acid substitutions that permit HIV-1 replication in the
presence of CsA. These mutations are localized to different areas
of the NTD: A92E and G94D in the CypA-binding loop (Aberham
et al., 1996; Braaten et al., 1996a), T54A in helix 3, (Yang and Aiken,
2007), N121K between helices 6 and 7 (Takemura et al., 2013), and
R132K in helix 7 (Schneidewind et al., 2007). Interestingly, these
mutants retain the ability to bind to CypA, and their replication is
actually dependent on CsA in some cell lines. For example, CsA is
required for replication of these mutants in HeLa and H9 cells but
not in Jurkat, HOS, or 293 T cells (Aberham et al., 1996; Braaten
et al., 1996a; Hatziioannou et al., 2005; Sokolskaja et al., 2004;
Yin et al., 1998). Thus, CypA binding to CA was detrimental on
replication in some cells. The infection impairment in HeLa cells is
genetically dominant, suggesting that they express a factor(s) that
restricts these mutants in a CypA-dependent manner (Song and
Aiken, 2007). The CsA-dependent mutant phenotype has recently
been linked to another capsid-binding protein, CPSF6 (Henning
et al., 2013) (discussed below). However the cell-type dependence
of the restriction has not yet been explained.
Lentiviruses, such as HIV-1, exhibit the unusual ability to infect
nondividing cells such as macrophages. This phenotype was
genetically mapped to the CA protein (Yamashita and Emerman,
2004; Yamashita et al., 2007). Similar to CsA dependence, several
cell-cycle dependent CA mutants (A92E, T54A, G94D, R132K) as
well as mutants having altered capsid stability (E45A and Q63A/
67 A) are selectively impaired for infection of nondividing HeLa
cells but not HOS cells or macrophages (Qi et al., 2008; Yamashita
and Emerman, 2009). Therefore, CsA dependence requires CypA-
CA interaction and differs between cell types. Interestingly, the
T54A CA mutant had only partially reduced reverse transcription
and showed a defect in nuclear import. An additional mutation in
the PF74 binding pocket, A105T, suppresses the CsA-dependent
phenotype and restores infectivity, suggesting that allosteric
changes distal to the CypA-binding loop alters the CA structure,
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thereby changing HIV-1 susceptibility to host restriction (Yang and
Aiken, 2007). In addition to restricting HIV-1 at an early stage of
the life cycle (e.g., prior to or at reverse transcription), rhTRIM5α
can restrict HIV-1 after nuclear entry of the viral DNA (Anderson
et al., 2006; Wu et al., 2006). The CypA-CA interaction also
contributes to rhTRIM5α restriction in nondividing cells (Yamashita
and Emerman, 2009). Thus, CypA also appears to inﬂuence nuclear
entry and the ability of HIV-1 to infect nondividing cells, which
requires translocation of the PIC across an intact nuclear membrane.
HIV-1 entry into nondividing myeloid lineage cells, such as
macrophages and dendritic cells (DCs), normally avoids activation
of innate immunity triggered by pathogen-associated molecular
patterns, such as cytoplasmic double-stranded DNA (Lahaye et al.,
2013; Manel et al., 2010; Rasaiyaah et al., 2013). In contrast,
infection by the closely related virus HIV-2 induces type 1 inter-
feron (IFN) production in DCs (Lahaye et al., 2013; Manel et al.,
2010). The lack of HIV-induced immunity in myeloid cells was
shown to be dependent on CA binding to CypA, as pharmacologic
inhibition of CypA binding to nascent Gag resulted in an innate
immune response (Manel et al., 2010; Rasaiyaah et al., 2013).
Similarly, HIV-1 CA mutants with reduced afﬁnity for CypA, such
as G89V and P90A, triggered immunity (Manel et al., 2010;
Rasaiyaah et al., 2013). In contrast, introduction of a CypA-
binding loop into HIV-2 suppressed its IFN activation, akin to
HIV-1 (Lahaye et al., 2013). Infection by a subset of HIV-1 CA
mutants in both cell types led to upregulation of cytoplasmic DNA
sensors that induce IRF3 translocation to the nucleus to induce IFN
(Lahaye et al., 2013; Rasaiyaah et al., 2013). These studies demon-
strate that HIV-1 escapes innate immune sensing and activation by
a stealth mechanism involving CypA-CA interactions. CypA stabi-
lizes the HIV-1 capsid in vitro (Shah et al., 2013), suggestive of a
capsid-speciﬁc mechanism for “cloaking” the viral DNA synthe-
sized during reverse transcription in the cytoplasm.
Activation of innate immune signaling by pathogens results in a
strong antiviral response via IFN induction of antiviral genes. One
of these encodes the IFN-induced myxovirus resistance 2 (MX2)
protein. MX2 inhibits HIV-1 infection by a mechanism involving
the viral capsid (Goujon et al., 2013; Kane et al., 2013; Liu et al.,
2013). The MX2-mediated block resulted in a reduction in nuclear
viral DNA and integration, which also was dependent on HIV-1 CA
and CypA. Interestingly, the N74D mutant was less susceptible to
inhibition by MX2 than WT HIV-1 (Goujon et al., 2013; Kane et al.,
2013), suggesting that CPSF6 may also play a role in MX2
inhibition of infection. Depletion of CypA also prevented MX2-
mediated restriction (Liu et al., 2013), suggesting that the CypA
binding to the HIV-1 capsid is involved in the antiviral mechanism.
Capsid uncoating inﬂuences nuclear import
In recent years, several additional cellular factors have been
shown to interact with CA and to affect HIV-1 infection. Trans-
portin 3 (TNPO3) is a karyopherin that binds arginine/serine (RS)-
rich proteins and was identiﬁed in screens for host factors required
for HIV-1 infection (Brass et al., 2008; Konig et al., 2008). The early
studies suggested that TNPO3 acts via by binding to IN and
promotes trafﬁcking of PICs to the nucleus (Christ et al., 2008).
However, the TNPO3 requirement was genetically linked to CA
(Krishnan et al., 2010), and infection by CA mutants having altered
capsid stability (e.g., E45A, N74D, and the PF74-resistant mutant)
was found to be less dependent on TNPO3 (De Iaco and Luban,
2011; Lee et al., 2010; Shah et al., 2013). These studies also showed
that TNPO3 depletion results in a defect in integration, rather than
nuclear entry. In addition, depletion of cellular TNPO3 reduces the
effectiveness of PF74 inhibition of WT HIV-1 but not the TNPO3-
independent CA mutants. Furthermore, addition of recombinant
TNPO3 to puriﬁed HIV-1 cores accelerated their disassembly
in vitro, and this was further stimulated in the presence of PF74.
Interestingly, CypA stabilized HIV-1 cores in vitro and antagonized
TNPO3-mediated uncoating, suggesting that CypA prevents pre-
mature uncoating of capsid in the cytoplasm and later disengages
the capsid, permitting completion of uncoating (Shah et al., 2013).
Collectively, these observations suggested that TNPO3 and CypA
coordinate to control HIV-1 uncoating in target cells, perhaps by
directly binding the capsid. However, more recent studies indicate
that TNPO3 acts indirectly, by sequestering CPSF6 (see below), and
promotes integration rather than nuclear entry (De Iaco and
Luban, 2011; De Iaco et al., 2013; Shah et al., 2013).
The cellular protein cleavage and polyadenylation speciﬁcity
factor 6 (CPSF6) is part of an mRNA processing complex that
shuttles between nucleus and cytoplasm (Ruegsegger et al., 1998).
Truncating the carboxyl-terminal region of CPSF6 (CPSF6-358)
results in a protein that is largely cytosolic and inhibits HIV-1
infection by preventing nuclear entry (Lee et al., 2010). Selection
for resistance to CPSF6-358 resulted in emergence of a virus
containing the N74D CA substitution, which inhibits binding to
CPSF6-358 (Lee et al., 2010; Price et al., 2012). Interestingly, the
CPSF6-binding pocket in CA overlaps the binding site for PF74
(Blair et al., 2010; Price et al., 2012), suggesting that the compound
may compete for CPSF6 binding in target cells.
HIV-1 uses the nuclear pore to gain entry into the nucleus by a
mechanism that depends on the viral capsid. The nuclear pore
complex includes nuclear pore proteins NUP153 and NUP358 (or
RanBP2), both of which were shown to be required for HIV-1
infection in the same screens that identiﬁed TNPO3 (Brass et al.,
2008; Konig et al., 2008). However, infection by the CPSF6-
independent mutant N74D HIV-1 does not depend on these
nucleoporins (Lee et al., 2010). Recently, it was shown that CA
binds directly to the NUP358 cyclophilin domain (Schaller et al.,
2011) and to NUP153 (Matreyek et al., 2013). Genetic studies
indicate that NUP153 interacts with a region of CA that overlaps
with the site at which PF74 and BI-2 bind (Matreyek et al., 2013).
It is possible that cytoplasmic pools of capsid-binding NUPs may
control uncoating by engaging the capsid. Alternatively, NUPs may
act directly on the core after docking to the nuclear pore. These
hypotheses are not mutually exclusive.
Price et al. proposed that CPSF6 binding to the HIV-1 capsid
facilitates its use of nuclear import factors such as TNPO3 and
nucleoporins (Price et al., 2012). Several lines of evidence support
this hypothesis. Two groups independently showed in cellular and
biochemical assays that TNPO3-dependence of HIV-1 infection is
correlated with the ability of CPSF6 to bind CA (De Iaco et al., 2013;
Fricke et al., 2013). Like N74D HIV-1, the A105T mutant is located
in the CPSF6/PF74-binding pocket and renders HIV-1 resistant to
inhibition by CPSF6-358 (De Iaco et al., 2013). Moreover, both
mutations restore infectivity to the cell-cycle dependent T54A
mutant (Henning et al., 2013). Collectively, studies of CPSF6-358-
resistant mutations (N74D or A105T) and CypA-independent or
CsA-dependent mutations (G89V and G94D) suggest that CPSF6
and CypA bind independently to HIV-1 capsid (Ambrose et al.,
2012; Henning et al., 2013), though the current evidence for this is
indirect.
A recent study showed that endogenous CPSF6 can inhibit
multiple CA mutants, including a naturally occurring double
mutant, R132K/L136M (Henning et al., 2013), which is selected
in patients who have the human leukocyte antigen (HLA)-B27
allele (Henning et al., 2013; Schneidewind et al., 2007). The HLA-
B27 allele encodes a particular major histocompatibility complex
(MHC) class I protein that presents certain peptides to CD8þ
T cells, and is associated with protection against AIDS progression
(Gao et al., 2005; Hendel et al., 1999). However, two CA mutations,
R132K and L136M arise in during infection of B27þ individuals
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and result in HIV-1 escape from cytotoxic T lymphocytes. These
substitutions were associated with accelerated disease progression
(Kelleher et al., 2001). Like N74D, the R132K/L136M variant
requires neither TNPO3 for infection nor either NUP153 or
NUP358 for nuclear entry. In vivo, compensatory mutations in CA
other than N74D emerge that conserve the dependence on these
host proteins, which suggests that CPSF6 and TNPO3/nucleoporin
use is advantageous for HIV-1 persistence in the host (Henning
et al., 2013).
Models of uncoating
Although there are many unanswered questions regarding HIV-1
uncoating, the collective data suggest a model (Fig. 1). First, based
on the recent studies of HIV-1 DNA sensing in myeloid cells (Lahaye
et al., 2013; Rasaiyaah et al., 2013), the model posits that CypA
prevents premature uncoating, thus facilitating reverse transcrip-
tion and subsequent engagement of the host proteins TNPO3 and
CPSF6 and subsequently NUP358 and NUP153, thereby permitting
uncoating and transport of PICs through nuclear pores (Fig. 1A).
NUPs, including NUP358 containing a CypA motif (Schaller et al.,
2011), are required for proper uncoating and nuclear trafﬁcking.
These results suggest that uncoating occurs at or near the nuclear
pore to allow safe passage through the cytoplasmwithout detection
by DNA sensors (Rasaiyaah et al., 2013). This view is supported by a
previous study of HIV-1 infection of cells using confocal and
electron microscopy techniques (Arhel et al., 2007).
Exposure of cells to some CA mutants induces type 1 IFN
production (Manel et al., 2010; Rasaiyaah et al., 2013) apparently
by undergoing premature uncoating (Fig. 1B). For example, the
N74D and P90A CA mutants fail to engage CPSF6 and CypA,
respectively, possibly resulting in rapid uncoating and exposure
of viral DNA, thus allowing detection by DNA sensors, such as
cGAS, and activation of innate immune responses. HIV-1 infection
of CPSF6- or CypA-depleted macrophages also induces type 1 IFN
secretion, which can induce MX2-mediated inhibition of nuclear
entry and integration.
Finally, premature uncoating by inhibitors and simian restric-
tion factors, such as rhTRIM5α and TRIMCyp, aborts reverse
transcription (Fig. 1C). It is possible that either exposed viral
RNA-DNA hybrids or small amounts of single- or double-strand
viral DNA could stimulate innate immunity. A lack of functional
PICs associated with CA, CPSF6, and TNPO3 will result in little
integrated viral DNA.
Conclusions and remaining questions
HIV-1 uncoating appears to be a tightly controlled process that
depends on proper capsid stability and interaction with multiple
host factors. Premature or delayed dissociation of capsid reduces
production of viral DNA and nuclear import of viral DNA, resulting
in abortive infection. Delayed uncoating also appears to be
deleterious to infection. Uncoating is a promising target for
antiretroviral therapy by small molecule inhibitors, and perturbing
this process may also allow virus control by IFN-induced restric-
tion factors.
Rapid progress on HIV-1 capsid structure and its interactions
with host factors has been made in the past decade. Nevertheless,
much remains to be learned. For example, molecular and spatio-
temporal aspects of uncoating, and the role of host factors in this
process, remain poorly understood. The mechanism by which
CypA protects the viral genome on its journey to the nucleus
and enhances inhibition by restriction factors is unclear. Studies of
uncoating in target cells are complicated by the apparently high
percentage of nonfunctional particles and by the small number of
cores that enter cells. New imaging technologies are needed to
deﬁne the precise steps of uncoating and where they occur.
Further research should also focus on the mechanism by which
Fig. 1. HIV-1 uncoating is linked to reverse transcription and nuclear import and requires host cell factors. (A) Core opening likely involves multiple steps and utilizes CypA
in a cell type-dependent manner to protect the viral DNA genome until nuclear entry, which is facilitated by CA binding of host cell proteins TNPO3, CPSF6, and components
of the nuclear pore complex (NUP153 and NUP358). (B) CA mutants, CypA depletion, and CPSF6 depletion induces premature uncoating distal from the nucleus. Exposed
viral DNA stimulates an innate immune response via detection of DNA sensors. The resulting IFN response induces expression of MX2, a host factor that prevents viral DNA
nuclear entry. (C) Uncoating is accelerated by small molecule inhibitors and nonhuman primate restriction factors, rhTRIM5α and TRIMCyp. Premature uncoating leads to
reduced reverse transcription and little nuclear import of viral DNA.
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the capsid binds and utilizes positive-acting host factors and how
it traverses the nuclear pore. Finally, differences in expression
of host cofactors for HIV-1 uncoating and nuclear import are
unknown, and it remains to be seen if interventions will be
effective in both CD4þ T cells as well as macrophages. Further
studies of HIV-1 capsid structure, stability, and interaction with
host factors will certainly lead to fascinating new insights about
this formidable human pathogen.
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